Results to your Biomarker

At the forefront of scientific development, ABF is leading the way with innovative methods for the accurate analysis of cannabis and cannabinoids. Risk assessment of these new products using appropriate biomarkers is becoming increasingly important, particularly for pharmacokinetic (PK) and toxicokinetic (TK) studies, exposure assessment and risk evaluation. Our cannabinoid panel encompasses THC, CBD, CBG and THCV in plasma. The bioanalytical method runs routinely according to GCP and GLP as part of our ISO 17025-accredited method portfolio in PK and TK studies. Our aim is to support you responsibly in the introduction of new products. ABF is your partner for reliable and innovative cannabinoid bioanalysis.